Description

Linovio-M OD 5/1GM ER is an oral antidiabetic medication designed to provide comprehensive blood glucose management in patients with type 2 diabetes mellitus. This combination therapy includes:

• Linagliptin (5 mg): A DPP-4 inhibitor that enhances incretin hormone activity, promoting insulin secretion and reducing glucagon levels, leading to better postprandial glucose control.
• Metformin Hydrochloride (ER) (500 mg): A biguanide that improves insulin sensitivity, decreases hepatic glucose production, and enhances peripheral glucose uptake while reducing gastrointestinal side effects due to its extended-release (ER) formulation.

This dual-action therapy effectively controls both fasting and postprandial blood sugar levels, helping to prevent diabetes-related complications. The extended-release (ER) formulation of Metformin ensures gradual drug release, leading to better tolerance and fewer digestive issues.

Linovio-M OD 5/1GM ER is an ideal choice for patients requiring a balanced approach to glycemic control, offering long-term diabetes management with enhanced efficacy and convenience.